肝血管瘤介入治疗的几点分歧

肝血管瘤是常见病，目前认为是一种先天性脉管畸形，其自发破裂的概率低，但一旦破裂有致命危险，近年来随着微创医学技术的发展，介入治疗以其创伤小、风险低、疗效显著的优势在肝血管瘤治疗中被临床与患者广泛接受，已成为治疗肝血管瘤的主要方法之一。然而肝血管瘤的介入治疗的适应症尚存争议，临床治疗中否存在过度治疗的问题有待进一步讨论，治疗方式的选择未有统一指南，治疗药物的选择及药物浓度的控制尚需进一步研究，治疗术后的疗效评估目前缺乏统一标准。本文就目前肝血管瘤介入治疗存在的几点分歧进行综述。 

Disagreement of interventional therapy of hepatic hemangioma

Liver hemangioma is a common disease. It is a congenital vascular malformation, the probability of spontaneous rupture of the low, but once the rupture is lethal, in recent years with the development of minimally invasive medical technology, interventional treatment with its small trauma, low risk, significant effect of the advantages in the treatment of liver hemangioma is widely accepted in clinical with the patient, has become one of the main methods for treatment of liver hemangioma. However, the interventional treatment of hepatic hemangioma indications are still controversial, over treatment issues to be discussed further the existence of the clinical treatment, treatment options no uniform guidelines, and control the concentration of drug therapy needs further study, evaluation of curative effect after treatment of the lack of unified standard. This article reviews the current differences in interventional therapy for hepatic hemangioma.